emerg
new
diseasecaus
coronaviru
gener
substanti
concern
june
middl
east
respiratori
syndrom
coronaviru
merscov
caus
laboratoryconfi
rmed
case
death
viru
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
sarscov
prepandem
stage
merscov
probabl
transmit
unknown
anim
host
human
be
repeatedli
past
year
case
humantohuman
transmiss
also
document
sever
countri
rais
import
question
merscov
potenti
caus
pandem
lancet
romulu
breban
colleagu
address
question
mathemat
epidemiologist
often
use
simpl
use
measur
call
basic
reproduct
number
r
averag
number
infect
caus
one
infect
individu
fulli
suscept
popul
r
greater
case
could
grow
exponenti
caus
fullblown
epidem
fi
gure
contrast
r
less
transmiss
guarante
fade
away
thing
equal
primari
task
upon
emerg
new
pathogen
estim
r
estim
r
prepandem
stage
plagu
data
uncertainti
variabl
howev
reason
first
learn
south
african
experi
import
new
weapon
war
smokingattribut
diseas
smoke
statu
year
death
note
regist
caus
death
ideal
everi
popul
underli
caus
death
assign
second
show
within
one
countri
smoke
caus
diff
erent
risk
diff
erent
subpopul
smoke
associ
lung
cancer
fi
rst
major
hazard
smoke
shown
also
cancer
cardiovascular
respiratori
diseas
estim
million
death
worldwid
caus
tobacco
past
centuri
current
smoke
habit
persist
could
well
billion
tobacco
death
centuri
well
tri
limit
vast
epidem
world
monitor
object
mani
diff
erent
popul
subpopul
popul
underli
caus
death
regist
corpor
one
easi
question
smoke
year
ago
death
notifi
cation
process
would
littl
expens
greatli
facilit
monitor
tobaccoattribut
mortal
countri
consid
follow
south
africa
exampl
number
secondari
infect
caus
index
case
highli
variabl
sometim
individu
highli
infecti
diseas
caus
infect
convers
individu
diseas
normal
low
infecti
occasion
caus
mani
infect
eff
ect
compound
small
number
confi
rmed
case
prepandem
stage
diffi
culti
identifi
whether
earliest
patient
infect
human
be
anim
addit
r
much
larger
ie
fair
chanc
transmiss
fade
anyway
henc
conclud
r
less
secondari
transmiss
seem
low
case
merscov
far
use
intuit
estim
whether
r
greater
less
might
accur
prepandem
stage
necessit
investig
use
statist
method
breban
colleagu
appli
specialis
statist
method
estim
r
merscov
care
construct
diff
erent
scenario
infect
recent
merscov
cluster
investig
comput
r
bestcas
worstcas
scenario
merscov
transmiss
tree
worstcas
scenario
r
ci
despit
small
number
confi
rmed
case
far
upper
ci
r
less
mean
merscov
unlik
caus
pandem
although
ci
might
also
use
estim
pandem
risk
addit
standard
interv
comparison
investig
estim
r
ci
prepandem
sarscov
southeast
asia
breban
colleagu
also
provid
calcul
enabl
r
estim
updat
inform
new
merscov
case
report
next
index
patient
infect
eight
individu
investig
estim
chanc
r
actual
worstcas
scenario
breban
colleagu
thorough
job
account
conclus
might
impact
qualiti
surveil
system
possibl
symptomat
mild
infect
network
structur
infect
within
merscov
cluster
factor
diffi
cult
account
investig
would
know
situat
might
chang
futur
exampl
recent
report
document
six
asymptomat
infect
addit
alli
r
might
chang
season
accord
climat
school
calendar
yearli
gather
pilgrimag
put
individu
closer
proxim
one
anoth
gather
involv
greater
contact
human
infect
anim
would
also
creat
opportun
diseas
introduct
anim
popul
anoth
potenti
futur
develop
merscov
might
start
evolv
sarscov
case
sarscov
sever
mutat
enabl
spike
glycoprotein
viru
bind
angiotensinconvert
enzym
human
receptor
make
much
easier
viru
infect
human
thu
probabl
increas
r
viru
evolut
present
particularli
relev
challeng
estim
r
seri
outbreak
distribut
time
approach
use
breban
colleagu
implicitli
assum
r
chang
henc
trend
antiretrovir
therapi
art
drug
recent
develop
gener
much
expect
hiv
integras
strand
transfer
inhibitor
dolutegravir
raltegravir
fi
rst
class
prove
valuabl
drug
treatment
initi
late
salvag
howev
era
daili
therapi
singl
tablet
regimen
domin
treatment
initi
market
raltegravir
rel
disadvantag
twice
daili
dose
secondinclass
integras
strand
transfer
inhibitor
elvitegravir
gain
us
food
drug
administr
approv
compon
new
fourinon
singl
tablet
regimen
stribild
gilead
scienc
inc
foster
citi
ca
usa
elvitegravir
requir
pharmacolog
boost
support
daili
dose
right
although
quadrupl
regimen
shown
noninferior
versu
fi
rst
singl
tablet
art
regimen
efavirenz
tenofovir
emtricitabin
atripla
gilead
scienc
inc
bristolmy
squibb
co
princeton
nj
usa
ritonavirboost
atazanavir
tenofovir
emtricitabin
need
boost
rel
drawback
increas
potenti
drugdrug
interact
elvitegravir
current
avail
singl
agent
thirdinclass
integras
strand
transfer
inhibitor
like
obtain
approv
possibl
within
next
year
dolutegravir
dolutegravir
halflif
support
daili
dose
therefor
fi
rst
standalon
daili
drug
class
dolutegravir
shown
noninferior
doubleblind
comparison
raltegravir
result
present
recent
confer
consist
dolutegravir
superior
effi
caci
artnaiv
particip
use
com
ponent
singl
tablet
regimen
combin
abacavir
lamivudin
doubleblind
comparison
atripla
lancet
pedro
cahn
colleagu
publish
result
sail
doubleblind
random
ise
control
comparison
dolut
gravir
versu
ralt
gravir
toward
increas
cluster
size
would
interpret
method
natur
variabl
unrel
viru
adapt
cluster
size
actual
grow
viru
evolv
higher
r
method
would
underestim
actual
evolv
r
therefor
signifi
canc
larg
new
cluster
might
misinterpret
method
allow
estim
r
rise
fall
time
might
captur
movement
toward
r
threshold
caus
viral
adapt
season
although
amount
data
avail
merscov
probabl
permit
present
maximis
chanc
contain
merscov
infect
need
continu
research
includ
updat
r
estim
methodolog
refi
nement
howev
analysi
breban
colleagu
conclud
merscovin
current
guisei
unlik
caus
pandem
depart
appli
mathemat
univers
waterloo
waterloo
canada
ctb
depart
mathemat
statist
univers
guelph
guelph
canada
ctb
cbauch
uwaterlooca
declar
confl
ict
interest
